We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK’s and Vir’s COVID-19 Monoclonal Antibody Gains Emergency Authorization
GSK’s and Vir’s COVID-19 Monoclonal Antibody Gains Emergency Authorization
GlaxoSmithKline’s (GSK) and Vir Biotechnology’s monoclonal antibody sotrovimab has secured FDA Emergency Use Authorization (EUA) for treating mild-to-moderate COVID-19 in patients 12 years and older at high risk of progressing to severe disease.